“Patients’ Quality of Life in a Phase 4 Real-World Study of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s135, https://doi.org/10.25251/skin.7.supp.135.